Day One Biopharmaceuticals Reports Strong 2025 Results, Pipeline Advancements, and 2026 Outlook

Key Highlights

• OJEMDA (tovorafenib) drives rapid revenue and prescription growth in 2025, with further acceleration forecasted for 2026.
• Company maintains a robust cash position of \$441.1 million as of year-end 2025, supporting an ambitious clinical pipeline.
• Pivotal data and regulatory milestones expected in 2026 and 2027 for both OJEMDA and key pipeline assets, notably Emi-Le and DAY301.
• Significant expansion opportunities identified in front-line pediatric low-grade glioma (pLGG) and adenoid cystic carcinoma (ACC).
• Positive long-term clinical results reinforce OJEMDA as a potential new standard of care in relapsed/refractory pLGG.
• No new safety signals observed in updated 3-year OJEMDA data.
• Potential share price catalysts include upcoming clinical readouts, regulatory submissions, and global commercial expansion.

Financial Performance: 2025 Review

Day One Biopharmaceuticals delivered exceptional year-over-year growth in OJEMDA net product revenue in 2025, reaching \$155.4 million (+172% YoY) with 4,635 prescriptions filled (+181% YoY). This robust performance was attributed to rapid market uptake following OJEMDA’s U.S. approval in April 2024 for relapsed or refractory pediatric low-grade glioma (pLGG) with BRAF rearrangements or V600 mutations. The company also reported total revenue of \$158.2 million for 2025, outpacing the prior year’s \$131.2 million.

Operating expenses for 2025 were \$285.9 million, reflecting ongoing R&D investment in pipeline programs and commercialization efforts. Despite a net loss of \$107.3 million, Day One ended 2025 with a strong cash, cash equivalents, and short-term investments balance of \$441.1 million, giving the company a solid runway for pipeline advancement and commercial execution.

2026 Outlook: Accelerated Growth and Major Clinical Milestones

Day One projects OJEMDA U.S. net product revenue of \$225–\$250 million in 2026, representing >50% growth over 2025. Management highlights commercial execution, deepening physician adoption, and increasing patient persistence as key drivers. The company is also transitioning ex-U.S. sales to Ipsen via partnership, with an anticipated global market expansion.

The company’s 2026 strategy focuses on solidifying OJEMDA as the second-line standard of care (SOC) in relapsed/refractory pLGG, while doubling the addressable opportunity through anticipated first-line (1L) approval, pending FIREFLY-2 trial data expected mid-2027. OJEMDA is poised to become a foundational therapy in both relapsed and frontline settings, with an estimated U.S. pLGG market of ~2,200 annual treatment decisions.

Pipeline Highlights: Multiple Potential Value Drivers

• OJEMDA (tovorafenib):
  • Received U.S. approval in April 2024 for relapsed/refractory pLGG with BRAF alterations.
  • 3-year follow-up data from the Phase 2 FIREFLY-1 trial show a median duration of response of 19.4 months and median time to next treatment of 42.6 months, with 77% of patients treatment-free at least 12 months after therapy. Minimal tumor rebound and retreatment feasibility were observed.
  • No new safety signals identified in 3-year safety update.
  • OJEMDA’s intellectual property is protected in the U.S. through at least mid-2036 (with potential extension), and regulatory exclusivities provide additional protection.
• FIREFLY-2 (pivotal Phase 3, frontline pLGG):
  • Enrollment expected to complete 1H 2026; topline data anticipated mid-2027, supporting a potential U.S. approval in 2028.
  • If approved, 1L indication could double OJEMDA’s commercial market.
• Emiltatug ledadotin (Emi-Le, B7-H4-targeted ADC):
  • Acquired through Mersana Therapeutics acquisition; targeting adenoid cystic carcinoma (ACC), a rare, treatment-resistant cancer with no approved therapies.
  • Phase 1 data readout expected mid-2026, with the potential for a rapid regulatory pathway due to high unmet medical need.
  • Annual U.S. ACC incidence is ~1,300 patients; high-value opportunity with potential for rapid adoption and time to peak sales.
• DAY301 (PTK7-targeted ADC):
  • First-in-class ADC for solid tumors; Phase 1a data expected 2H 2026.
  • Patent protection expected through 2044 (once issued).

Market Opportunity and Commercial Execution

OJEMDA’s addressable market in relapsed/refractory pLGG is estimated at ~1,100 annual treatment decisions, with substantial headroom for growth as current penetration reflects only a portion of the eligible population. With the anticipated expansion into the frontline setting, OJEMDA could address the full continuum of pLGG treatment, potentially doubling its revenue base.

The company’s commercial strategy includes driving new patient starts, reinforcing OJEMDA’s clinical profile with ongoing evidence generation, and supporting persistence through physician and patient education. The transition of ex-U.S. rights to Ipsen is expected to further enhance global reach and revenue.

Intellectual Property and Regulatory Protection

OJEMDA is covered by a robust patent estate in the U.S. and abroad, with exclusivity potentially extending well into the 2040s. Regulatory exclusivities, including Orphan Drug and New Chemical Entity status in the U.S. and Europe, further strengthen the product’s market position.

Potential Share Price Catalysts

• Pivotal data readouts for OJEMDA in both relapsed/refractory and frontline pLGG (FIREFLY-1 and FIREFLY-2 trials).
• Phase 1 efficacy and safety data for Emi-Le in ACC (mid-2026).
• Phase 1a data for DAY301 in solid tumors (2H 2026).
• Continued commercial revenue growth and global market expansion with Ipsen.
• Potential regulatory submissions and approvals for expanded OJEMDA indications (including frontline pLGG in 2028).

Risks and Considerations for Shareholders

• Uncertainties remain regarding regulatory outcomes, competitive landscape, and market uptake, particularly for pipeline assets.
• Ongoing R&D spending and negative net income may impact near-term profitability.
• Macroeconomic factors, such as inflation, supply chain disruptions, and global/regional conflicts, could impact operations.
• Forward-looking statements are subject to material risks and uncertainties, as detailed in the company’s filings with the SEC.

Conclusion

Day One Biopharmaceuticals is entering a potentially transformational period in 2026, with strong financial resources, accelerating revenue growth, and a diversified pipeline targeting significant unmet needs in pediatric and adult oncology. Multiple upcoming clinical and regulatory milestones across OJEMDA, Emi-Le, and DAY301 represent key value inflection points and may drive share price appreciation. Investors should closely monitor the company’s progress on these fronts, as well as any updates regarding global commercialization and competitive positioning.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Forward-looking statements are inherently subject to risks and uncertainties. Investors should consult the company’s filings and disclosures and consider their own financial situation before making investment decisions.

View Day One Biopharmaceuticals, Inc. Historical chart here